In this study, we present the discovery, mechanistic insights, and preclinical validation of a potent, selective small-molecule drug candidate with dual PROTAC and molecular glue mechanisms that target human androgen receptors. This drug lead shows remarkable therapeutic potential on various drug-resistant prostate cancers.